Related Experiment Video
Updated: Jan 14, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Oncologists' Views and Communication Practices Regarding Unproven High-Cost Cancer Interventions in Private Medical
Tsunakuni Ikka1,2, Taichi Hatta3, Noriyuki Katsumata4
1Division of Bioethics & Healthcare Law, Institute for Cancer Control, National Cancer Center Japan, Chuo-ku, Japan.
Abstract:
IntroductionIn Japan, while public health insurance ensures evidence-based-care, high-cost private medical practices offer advanced interventions-collectively referred to as "X" in this study-which have limited scientific evidence but have raised ethical and clinical concerns, particularly in oncology. This study explores oncologists' perceptions and responses to X in practice to inform appropriate countermeasures.MethodsMembers of the Japanese Society of Medical Oncology (n = 6273) completed a questionnaire survey between April 24 and June 10, 2024. The survey explored the oncologists' evaluations of X, their responses to patient inquiries about such interventions, and their personal preferences if they were personally diagnosed with cancer.ResultsOf 828 valid responses (response rate: 13.2%), 63.4% of oncologists reported receiving patient inquiries about X in the past year. Overall, 76.4% gave a negative evaluation of X, while over 90% provided negative ratings on 7 out of the 9 specific items. Despite this, many oncologists reported a neutral stance when discussing X with the patients. Notably, even without standard of care options, most indicated that they would not choose X for themselves. The findings reveal a considerable gap between oncologists' evaluation of X and what they convey when communicating with the patients. Qualitative responses expressed concerns about insufficient follow-up care and potential exploitation of vulnerable patients.ConclusionThis study highlights the need for more transparent, evidence-based communication between oncologists and patients regarding X. Enhancing such dialogue is essential for supporting informed decision-making and maintaining the integrity of cancer care in the face of unproven private medical interventions. Furthermore, considering X's profound negative impact on patients, society, and the field of medicine, legitimate medical professionals must conduct clear and accurate evaluations of X to facilitate the understanding of the patients and general public.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...